Revance Therapeutics

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revance Therapeutics excels in Q4 with DAXXIFY approval driving growth

Revance Therapeutics demonstrated strong financial performance and strategic focus in Q4 2022, driven by DAXXIFY sales and revenue growth.
The company's strengths lie in DAXXIFY approval, positive market feedback, and partnerships positioning them well for future growth.
Challenges include competitive dynamics, pricing strategies, and managing increased OpEx, while opportunities exist in market expansion and new product programs.
Overall, Revance is optimistic about their market position and future prospects, emphasizing customer relationships and strategic investments.

Revance Therapeutics posts stellar Q1 results, eyes market expansion

Revance Therapeutics delivered strong Q1 results, driven by robust RHA Collection and DAXXIFY sales, positioning the company for future growth.
While facing challenges in undisclosed market data and paused clinical trials, Revance's strategic focus on market entry and product adoption presents opportunities for expansion.
With a solid cash position, upcoming milestones, and market potential, Revance is poised for continued success in the neuromodulator and therapeutics segments.

Revance Therapeutics reports record revenue growth and strategic expansion

Revance Therapeutics had a robust Q2 2023, marked by strong revenue growth, expanded sales force, and successful marketing efforts.
While facing challenges in market reception and adoption rates for DAXXIFY, the company remains optimistic about driving growth and leveraging opportunities.
With a focus on sales force expansion, product education, and strategic initiatives, Revance is poised for continued commercial progress and success.

Revance Therapeutics reports strong Q3 growth driven by DAXXIFY

Revance Therapeutics is strategically focusing on DAXXIFY launch success, aesthetics growth, and therapeutics opportunities. Despite challenges in account responses and revenue guidance uncertainties, the company remains optimistic about expanding DAXXIFY adoption and maintaining a strong financial position.

Revance Therapeutics reports record revenue, eyes growth in 2024

Revance Therapeutics had a strong performance in 2023, focusing on growth and cost controls for future success.
The company's strategic initiatives and product offerings position it well for continued growth and market expansion.
Challenges in managing expenses and achieving profitability are being addressed with targeted strategies.
Optimism surrounds the potential of DAXXIFY and the company's ability to capitalize on market opportunities.

Revance Therapeutics (RVNC) reports strong Q1 performance and strategic market entry

Revance Therapeutics (RVNC) demonstrated strong performance in Q1 2024, driven by growth in DAXXIFY and RHA filler market share, with a strategic entry into the therapeutic neurotoxin market.
The company's focus on innovation, efficiency, and market expansion presents opportunities for revenue growth and competitive positioning, despite challenges in differentiation and market dynamics.
Efforts to drive product adoption, enhance customer engagement, and optimize operational efficiency underscore Revance's commitment to sustainable financial health and long-term success.
Overall, Revance's Q1 performance reflects positive momentum and strategic initiatives aimed at capitalizing on market opportunities and strengthening its competitive position.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock

Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock

FDA approves Revance Therapeutics' (RVNC) Daxxify as a long-acting neuromodulator with a strong label that includes 36-week efficacy data from the SAKURA clinical program.

Revance (RVNC) Gets FDA Nod for Anti-Wrinkle Product, Stock Up

Revance Therapeutics says its new treatment, Daxxify, diminishes facial wrinkles for up to six months.

Revance Shares Jump 17% After FDA Approves Botox Rival

Revance Therapeutics (NASDAQ: RVNC ) stock is jumping 12% and trending on social media today. The company announced this morning that the Food and Drug Administration (FDA) had approved its alternative to Botox.

Why Is Revance Therapeutics (RVNC) Stock Soaring Today?

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces FDA Approval of DAXXIFY™ for injection, the First and Only Peptide-Formulated Neuromodulator with Long-Lasting Results

Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results

Revance Therapeutics, Inc. (NASDAQ:RVNC ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Jessica Serra - Head-Investor Relations and ESG Mark Foley - Chief Executive Officer Toby Schilke - Chief Financial Officer Conference Call Participants Operator Welcome to the Revance Therapeutics Second Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q2 2022 Results - Earnings Call Transcript

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update

Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference

Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference

Resubmission of BLA for DAXI for glabellar lines achieved, PDUFA date established for September 8, 2022. The global Botulinum Toxin market is expected to reach $7.71 billion by 2027.

Revance: Potential Comeback On FDA Resubmission For DAXI

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in the William Blair 42nd Annual Growth Stock Conference

Revance to Participate in the William Blair 42nd Annual Growth Stock Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Jessica Serra – Head-Investor Relations and ESG Mark Foley – Chief Executive Officer Dustin Sjuts – President Toby Schilke – Chief Financial Officer Conference Call Participants Ken Cacciatore – Cowen and Co Seamus Fernandez – Guggenheim David Amsellem – Piper Sander Annabel Samimy – Stifel Balaji Prasad – Barclays Vamil Divan – Mizuho Securities Douglas Tsao – H.C. Wainwright Rohit Bhasin – Needham Operator Welcome to the Revance Therapeutics' First Quarter 2022 Financial Results and Corporate Update Conference Call.

Revance Therapeutics's (RVNC) CEO Mark Foley On Q1 2022 Results - Earnings Call Transcript

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update

Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release First Quarter Financial Results on Tuesday, May 10, 2022

Revance to Release First Quarter Financial Results on Tuesday, May 10, 2022

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines

Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance To Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 AAN Annual Meeting

Revance to Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology Annual Meeting

AstraZeneca

Regeneron Pharmaceuticals

Should you be paying attention to these biotech stocks right now?

3 Top Biotech Stocks To Watch This Week

Revance Therapeutics, Inc. (RVNC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 8.7% Jump Turn into More Strength?

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management

Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Resubmits Biologics License Application for DaxibotulinumtoxinA for Injection for Glabellar Lines to the FDA

Revance Resubmits Biologics License Application for DaxibotulinumtoxinA for Injection for Glabellar Lines to the FDA

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in the Cowen 42nd Annual Health Care Conference

Revance to Participate in the Cowen 42nd Annual Health Care Conference

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q4 2021 Results - Earnings Call Transcript

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Fourth Quarter and Full Year 2021 Financial Results, Provides Corporate Update

Revance Reports Fourth Quarter and Full Year 2021 Financial Results, Provides Corporate Update

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

Revance to Release Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Revance Therapeutics Stock (RVNC)